https://scholars.lib.ntu.edu.tw/handle/123456789/579129
標題: | Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas | 作者: | Lin B.J. HUEY-PEIR WU Huang H.S. Huarng J. Sison A. Bin Abdul Kadir D.K. Cho C.-G. Sridama W. |
關鍵字: | Acarbose; Asian type 2 diabetes mellitus; Efficacy; Glycemic control; Tolerability | 公開日期: | 2003 | 出版社: | Elsevier Inc. | 卷: | 17 | 期: | 4 | 起(迄)頁: | 179-185 | 來源出版物: | Journal of Diabetes and its Complications | 摘要: | The objective of this study was to investigate the efficacy, tolerability, and safety of acarbose in the improvement of glycemic control in Asian patients with type 2 diabetes inadequately controlled by diet and sulfonylureas. A 24-week, double-blind, placebo-controlled multicenter group comparison study was conducted. Patients were randomized to receive acarbose titrated up to 100-mg tid (n=36) or matching placebo (n=33). Concomitant sulfonylurea treatment remained unchanged throughout the study. The primary efficacy parameter was the change in HbA1c from baseline to double-blind endpoint. Secondary efficacy variables consisted of the change from baseline to endpoint in blood glucose (fasting and 1-h postprandial), serum insulin (fasting and 1-h postprandial), and urinary glucose. In the intention-to-treat (ITT) analysis, acarbose treatment was associated with significantly greater reductions in glycated hemoglobin (HbA1c) (-0.91% vs. placebo 0.13%, P=.0018) and 1-h postprandial blood glucose levels (-2.84 mmol/l vs. placebo -0.28 mmol/l, P=.002) compared to placebo. There were no significant differences between the treatment groups regarding changes in fasting blood glucose, fasting or 1-h postprandial serum insulin, urinary glucose, or body weight. Adverse events occurred with similar frequency in both treatment arms except for drug-related gastrointestinal side-effects associated with acarbose (acarbose 48.5% and placebo 12.5%). This study has shown that the use of acarbose in Asian patients with type 2 diabetes inadequately controlled by diet and sulfonylureas is efficacious in improving metabolic control and that acarbose is safe and well tolerated. ? 2003 Elsevier Inc. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0142029443&doi=10.1016%2fS1056-8727%2802%2900258-1&partnerID=40&md5=87babd4d64eb5d3d56bf770af99415b4 https://scholars.lib.ntu.edu.tw/handle/123456789/579129 |
ISSN: | 1056-8727 | DOI: | 10.1016/S1056-8727(02)00258-1 | SDG/關鍵字: | acarbose; biguanide derivative; glucocorticoid; insulin; ispagula; placebo; sulfonylurea derivative; abdominal distension; abdominal pain; adult; adverse drug reaction; aged; anorexia; article; asthenia; clinical article; clinical trial; constipation; controlled clinical trial; controlled study; diabetic diet; diarrhea; double blind procedure; drug efficacy; drug tolerability; dyspepsia; dyspnea; female; flatulence; gangrene; gastrointestinal symptom; human; male; multicenter study; non insulin dependent diabetes mellitus; priority journal; randomized controlled trial; treatment outcome; vertigo; vomiting |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。